title: Mucocutaneous disorders in renal transplant recipients receiving sirolimus-based immunosuppressive therapy: a prospective, case-control study.
abstract: BACKGROUND
  Sirolimus (SRL) has some dermatologic complications including acneiform eruptions, edema, aphthous ulceration, and onychopathy. However, controlled studies reporting the prevalence and clinical characteristics of mucocutaneous disorders are scarce.
  
  
  OBJECTIVE
  To investigate the prevalence and clinical spectrum of mucocutaneous disorders in renal transplant recipients (RTRs) receiving SRL and to compare the findings with those in RTRs not receiving SRL.
  
  
  METHODS
  Fifty RTRs (35 men, 15 women; mean age, 34.6 ± 11.6 yr) receiving SRL, 50 RTRs (36 men, 14 women; mean age, 34.4 ± 11.3 yr) not on SRL were screened for mucocutaneous disorders.
  
  
  RESULTS
  In RTRs receiving SRL, skin infection (78%) was the most common dermatologic disorder followed by facial hyperpigmentation (50%) and acneiform eruption (46%). Herpes simplex virus infections (14%) and seborrheic dermatitis (38%) were significantly more common in RTRs on SRL (p < 0.05); the frequencies of edema, aphthous ulceration, acne, and longitudinal nail ridging were similar in both groups (p > 0.05).
  
  
  CONCLUSIONS
  This study had a small sample size. The investigator was not blinded to immunosuppressive treatment protocols.
  
  
  CONCLUSIONS
  Renal transplant recipients receiving SRL are more likely to develop seborrheic dermatitis and herpes simplex virus infections than those not taking SRL. Whereas, they are not more prone to edema, aphthous ulceration, acne, or longitudinal nail ridging.
authors.affiliation: Department of Dermatology, Başkent University Faculty of Medicine, Ankara, Turkey.
authors.forename: Deren
authors.initials: D
authors.lastname: Özcan
authors.forename: Deniz
authors.initials: D
authors.lastname: Seçkin
authors.forename: Simin
authors.initials: S
authors.lastname: Ada
authors.forename: Mehmet
authors.initials: M
authors.lastname: Haberal
mesh_terms: D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000150:complications / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D009092:Mucous Membrane / Q000187:drug effects* / Q000473:pathology; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors; D020123:Sirolimus / Q000009:adverse effects*; D012874:Skin Diseases, Infectious / Q000139:chemically induced* / Q000473:pathology; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus
keywords: adverse effects; immunosuppression; mucocutaneous; organ transplantation; renal; sirolimus